ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R.
Aceves-Luquero CI, et al.
PLoS One. 2009 Jul 1;4(7):e6124. doi: 10.1371/journal.pone.0006124.
PLoS One. 2009.
PMID: 19568437
Free PMC article.